Three drugmakers with products in short supply have some homework to do, courtesy of a new House committee probe. By sending letters to executives at Teva, Sandoz and Pfizer, Democratic members of the ...

There are actually two factors to consider in the current drawdown. The first is the massive stock price spike that occurred during the coronavirus pandemic. Pfizer was one of a small number of ...

Pfizer's business may be in better shape than investors think.

The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. Come mid-February, Pfizer will lay off ...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.